These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 35528950)

  • 41. Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study).
    Molnár GA; Vokó Z; Sütő G; Rokszin G; Nagy D; Surján G; Surján O; Nagy P; Kenessey I; Wéber A; Pálosi M; Müller C; Kásler M; Wittmann I; Kiss Z
    BMJ Open Diabetes Res Care; 2024 Jan; 12(1):. PubMed ID: 38267204
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of Antibody Response and Adverse Effects following Heterologous COVID-19 Vaccine Booster with mRNA Vaccine among Healthcare Workers in Indonesia.
    Soegiarto G; Mahdi BA; Wulandari L; Fahmita KD; Hadmoko ST; Gautama HI; Prasetyaningtyas D; Prasetyo ME; Negoro PP; Arafah N; Purnomosari D; Tinduh D; Husada D; Baskoro A; Fetarayani D; Nurani WK; Oceandy D
    Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514976
    [No Abstract]   [Full Text] [Related]  

  • 43. Correlation between COVID-19 vaccination and diabetes mellitus: A systematic review.
    He YF; Ouyang J; Hu XD; Wu N; Jiang ZG; Bian N; Wang J
    World J Diabetes; 2023 Jun; 14(6):892-918. PubMed ID: 37383586
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare Workers.
    Dechates B; Porntharukchareon T; Sirisreetreerux S; Therawit P; Worawitchawong S; Sornsamdang G; Soonklang K; Tawinprai K
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992267
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serological response to vaccination against coronavirus disease-19 in patients with inflammatory bowel disease.
    Mathur A; Sahu S; Rai S; Ghoshal U; Ghoshal UC
    Indian J Gastroenterol; 2023 Feb; 42(1):64-69. PubMed ID: 36598745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine.
    Rangsrisaeneepitak V; Porntharukchareon T; Dechates B; Sirisreetreerux S; Tawinprai K
    Diabetol Int; 2022 Oct; 13(4):637-643. PubMed ID: 35528950
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population.
    Sirisreetreerux S; Porntharukchareon T; Dechates B; Rangsrisaeneepitak V; Therawit P; Worawitchawong S; Sornsamdang G; Soonklang K; Tawinprai K
    Sci Rep; 2023 Jul; 13(1):11798. PubMed ID: 37479776
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population.
    Tawinprai K; Siripongboonsitti T; Porntharukchareon T; Dechates B; Monprach H; Sornsamdang G; Wittayasak K; Soonklang K; Mahanonda N
    Hum Vaccin Immunother; 2022 Dec; 18(1):2035573. PubMed ID: 35240945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal Study.
    Mishra SK; Pradhan SK; Pati S; Sahu S; Nanda RK
    Cureus; 2021 Nov; 13(11):e19879. PubMed ID: 34976499
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial.
    Asano M; Okada H; Itoh Y; Hirata H; Ishikawa K; Yoshida E; Matsui A; Kelly EJ; Shoemaker K; Olsson U; Vekemans J
    Int J Infect Dis; 2022 Jan; 114():165-174. PubMed ID: 34688944
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India.
    Kulkarni PS; Padmapriyadarsini C; Vekemans J; Bavdekar A; Gupta M; Kulkarni P; Garg BS; Gogtay NJ; Tambe M; Lalwani S; Singh K; Munshi R; Meshram S; Selvavinayagam TS; Pandey K; Bhimarasetty DM; Ramakrishnan SR; Bhamare C; Dharmadhikari A; Vadakkedath R; Bonhomme CJ; Thakar M; Kurle SN; Kelly EJ; Gautam M; Gupta N; Panda S; Bhargava B; Shaligram U; Kapse D; Gunale B;
    EClinicalMedicine; 2021 Dec; 42():101218. PubMed ID: 34870133
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
    Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
    Front Immunol; 2021; 12():752233. PubMed ID: 34899701
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: The CAVEAT study.
    Marfella R; D'Onofrio N; Sardu C; Scisciola L; Maggi P; Coppola N; Romano C; Messina V; Turriziani F; Siniscalchi M; Maniscalco M; Boccalatte M; Napolitano G; Salemme L; Marfella LV; Basile E; Montemurro MV; Papa C; Frascaria F; Papa A; Russo F; Tirino V; Papaccio G; Galdiero M; Sasso FC; Barbieri M; Rizzo MR; Balestrieri ML; Angelillo IF; Napoli C; Paolisso G
    Diabetes Obes Metab; 2022 Jan; 24(1):160-165. PubMed ID: 34494705
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.